Group items tagged

The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

The NIGMS Postdoctoral Research Associate (PRAT) Programs overarching goal is to provide high quality postdoctoral research training in the basic biomedical sciences, in NIH intramural research laboratories, to a diverse group of postdoctoral fellows to prepare them for leadership positions in biomedical careers. The research projects proposed should focus on NIGMS mission-related areas of basic biomedical science. These include cell biology, biophysics, genetics, developmental biology, pharmacology, physiology, biological chemistry, computational biology, technology development and bioinformatics. Studies employing model organisms are encouraged

Pathway supports innovative basic, clinical, translational, epidemiological, behavioral, or health services research relevant to any diabetes type, diabetes-related disease state, or diabetes complication. The Association seeks exceptional candidates from a broad range of disciplines, including medicine, biology, chemistry, computing, physics, mathematics and engineering.

Research proposals are sought from educational institutions, nonprofit organizations, and commercial organizations for research in materials sciences; ballistics and aeromechanics sciences; information sciences; human sciences; survivability, lethality, and vulnerability analysis and assessment; chemistry; electronics; physics; environmental sciences; life sciences; mechanical sciences, mathematical sciences, computing sciences and network sciences. Proposals will be evaluated only if they are for scientific study and experimentation directed toward advancing the state of the art or increasing knowledge and understanding. ARO has primary responsibility for ARL's extramural basic research programs, with specific research interests as described in Part II.A.2. The ARL Directorates, while having primary responsibility for ARL's in-house research programs, also manage select extramural basic research programs. The research interests of the Directorates are described in Part II.A.1. Although ARL Directorates will consider funding proposals for extramural research programs, they can fund only a modest number of proposals in a single fiscal year.

The prize is awarded to an individual in a selected area of chemistry who has done exceptional and original research that has advanced the field in a major way. The prize is awarded biennially and consists of a monetary award of $250,000, a medal, and a certificate.

The purpose of this funding opportunity announcement (FOA) is twofold: 1. to accelerate translational and clinical Phase I and II a/b safety and efficacy studies for substantiating measurable functional benefits of probiotic/prebiotic components and/or their combinations; and; 2. to understand the underlying mechanisms of their action(s), and variability in responses to these interventions. This FOA calls for interdisciplinary collaborations across scientific disciplines engaged in microbiome and pro/prebiotic research including, but not limited to: nutritional science, microbiology, virology, microecology and microbiome, genomics, immunology, computational biology, chemistry, bioengineering, as well as integration of omics and computational approaches in DNA technologies.

The U.S. Environmental Protection Agency (EPA), through its Science to Achieve Results (STAR) program, seeks applications for research on how pollution affects human health in the context of the total environment - built, natural, and social environments interacting together with inherent characteristics and interactions. Proposed research should develop and test innovative models or impact assessment approaches to examine causal relationships of chemical pollutants and health effects with modifying interactions among the variables representing all of the major stressors and factors involved in a person's life. Proposals that integrate a diverse field of disciplines (social science, economics, epidemiology, engineering, environmental science, biology, statistics, toxicology, chemistry, etc.) to address the complexity of the total environment research problem are highly recommended.

In celebrating its 350th anniversary, Merck KGaA, Darmstadt, Germany offers a series of research grants to stimulate innovative research in challenging areas of future importance. Merck KGaA, Darmstadt, Germany intends to provide several research grants of up to EUR 350,000 per year for 3 years in various research areas with the option of extension or expansion. Grants are offered for research in the following areas: Healthy Lives / Drug Discovery: Challenge 1: What is the next game-changing molecule or technology to help cure cancer or autoimmune disease? Life Reimagined / Synthetic Biology: Challenge 1: What is the next generation production technology for biologics? Challenge 2: Can you revolutionize microbiome research? Materials & Solutions: Challenge 1: Can you develop a new generation of intelligent materials? Challenge 2: Can you develop advances in characterization, control and surface chemistry? Challenge 3: Can you develop better atomic layer processes - from modelling to materials? Digitalization / Computing: Challenge 1: How can in-silico research benefit from deep learning or quantum computing?

Purpose This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems essential to the development of functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be proof-of-concept prototype biodevices, dedicated biosensors, associated core technologies and integrated approaches that enable development of safe and effective intra-oral biodevices intended for specific clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.

The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease.  The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research.

To foster innovative collaborative approaches to research projects that propose novel pairings of investigators from at least two broadly disparate disciplines. The proposal must focus on the collaborative relationship, such that the scientific objectives could not be achieved without the efforts of at least two co-principal investigators and their respective disciplines. The combination and integration of studies may be inclusive of basic, clinical, population, behavioral, and/or translational research. Projects must include at least one Co-PI from a field outside cardiovascular disease and stroke. This award is also intended to foster collaboration between established and early- or mid-career investigators. Applications by existing collaborators are permitted, provided that the proposal is for a new and novel idea or approach that has not been funded before. Multidisciplinary research broadly related to cardiovascular function, cardiovascular disease, and stroke, or to related clinical, basic science, bioengineering, biotechnology, or public health problems. Proposals are encouraged from all basic science disciplines as well as epidemiological, behavioral, community and clinical investigations that bear on cardiovascular and stroke problems. AHA awards are open to the array of academic and health professionals. This includes but is not limited to all academic disciplines (biology, chemistry, engineering, mathematics, technology, physics, etc.) and all health-related professions (physicians, nurses, advanced practice nurses, pharmacists, dentists, physical and occupational therapists, statisticians, nutritionists, behavioral scientists, health attorneys, engineers, etc.).

The purpose of the NLA Junior Faculty Research is to encourage scholarly advancement of Junior Faculty in the pursuit of a career related to hyperlipidemia and other lipid disorders in humans. The NLA will fund eligible institutions to provide $70,000 per year in salary support for those actively involved in clinical and/or basic science that provides promise of developing new information in fields of study that could advance the diagnosis and management of lipid disorders such as biochemistry, physiology, or genetics as well as interventions that improve therapy. The institutions eligible shall be nonprofit and offer an environment that would logically support a young faculty member with appropriate equipment, space and experienced faculty for proposed studies. The proposal will identify a specific candidate with training and strong signs of early success in an appropriate area of research and with a plan for developing appropriate experiments or clinical studies. To be eligible, an applicant is expected to hold or be eligible for a doctoral level degree (PhD, PharmD or MD) prior to the date of the scheduled award. There must be a record of accomplishment in a relevant research area as manifest by publications or a PhD thesis of high quality. The application for the Basic Science Award may focus on any aspect of lipid metabolism that has relevance to human disease. This may include experiments at the laboratory bench involving structural chemistry, biochemistry, physiology or genetics.

The INSPIRE awards program was established to address some of the most complicated and pressing scientific problems that lie at the intersection of traditional disciplines.  It is intended to encourage investigators to submit bold, exceptional proposals that some may consider to be at a disadvantage in a standard NSF review process; it is not intended for proposals that are more appropriate for existing award mechanisms.

DARPA is soliciting innovative research proposals of interest to the Defense Sciences Office. Proposed research should investigate innovative approaches that enable revolutionary advances in science and technology. Specifically excluded is research that results primarily in evolutionary improvements to the existing state of the art.

The National Institute on Drug Abuse (NIDA) supports a program of longitudinal cohorts to address emerging and high priority research on HIV/AIDS in the context of injection and non-injection substance abuse.  These cohorts provide a strong resource platform for current and future collaborative efforts with other investigators to address emerging questions related to HIV pathogenesis, prevention, and treatment in the context of substance abuse, as well as to foster the creativity and efficiency of investigator-initiated research projects. The diverse research activities among these cohorts include basic immunologic, and virologic studies, as well as studies on HIV prevention and treatment, and the co-morbidities and co-infections associated with HIV and substance abuse.  NIDA has determined that a coordinating center (CC) is needed in order to take advantage of these rich sources of data and bio-specimens and optimize collaborations among both the cohort investigators and other researchers not funded under the cohort program. In addition, the CC is expected to establish a virtual repository, and facilitate the leadership of the cohorts steering committee (SC), consisting of representatives from the NIDA-funded cohorts and NIDA staff. At this time, NIDA is soliciting  cooperative agreement applications for a CC to support the collaborative efforts of the cohorts that are currently funded by NIDA.

This initiative will support research projects that implement and test comprehensive service approaches to engage and retain youth and young adults (age 12 - 25 years) from health disparity populations in the HIV Treatment Cascade, which includes diagnosis, linkage to care, engagement in care, retention in care, initiation of antiretroviral therapy (ART), and achievement of viral suppression.   

A central goal of the BRAIN Initiative is to understand how electrical and chemical signals code information in neural circuits and give rise to sensations, thoughts, emotions and actions. While currently available technologies can provide some understanding, they may not be sufficient to accomplish this goal. For example, non-invasive technologies are low resolution and/or provide indirect measures such as blood flow, which are imprecise; invasive technologies can provide information at the level of single neurons producing the fundamental biophysical signals, but they can only be applied to tens or hundreds of neurons, out of a total number in the human brain estimated at 85 billion. Other BRAIN FOAs seek to develop novel technology (RFA-NS-16-006) or to optimize existing technology ready for in-vivo proof-of-concept testing and collection of preliminary data (RFA-NS-16-007) for recording or manipulating neural activity on a scale that is beyond what is currently possible. This FOA seeks applications for unique and innovative technologies that are in an even earlier stage of development than that sought in other FOAs, including new and untested ideas that are in the initial stages of conceptualization.

The Common Fund Program - Accelerating Translation of Glycoscience: Integration and Accessibility - aims to develop accessible and affordable new tools and technologies for studying carbohydrates that will allow biomedical researchers to significantly advance our understanding of the roles of these complex molecules in health and disease. This program will enable investigators who might not otherwise conduct research in the glycosciences, to undertake the study of carbohydrate structure and function. In support of these aims, this FOA seeks applications for a community-driven project to develop computational and informatics tools for the manipulation, analysis, interpretation, and integration of glycoscience data. The product of this research will be accessible resources for analysis of carbohydrate and glycoconjugate structural, analytical, and interaction data, and integration of that information within the context of comparable gene, protein, and lipid data and databases.  

This FOA solicits development of innovative adaptations of existing technologies to enable their use for readily identifying, manipulating, or analyzing glycans and their biological binding partners. This may encompass the adaptation of commonly used laboratory-based or computational tools to enable their facile application to glycoscience for the first time, as well as the adaptation of tools presently used by specialists in glycoscience to make them significantly more straightforward and accessible for non-specialists. It is possible that a project might simplify a current specialized approach by migrating it to a more commonly used platform, developing automation for data acquisition and interpretation, or redesigning the present tool to make it easier to use. This announcement differs from the related FOA RFA- RM-16-022 which solicits new or more effective tools or technologies, thus representing an expansion of existing technologies.

The Gulf of Mexico Research Initiative (GoMRI) announced today that it plans to award up to $105 million to support research consortia investigating the effect, and the potential associated impact, of hydrocarbon releases on the environment and public health, as well as to develop improved spill mitigation, oil detection, characterization, and remediation technologies.  The funding under this program, known as RFP-IV, will support research in the Gulf of Mexico conducted by consortia of four or more institutions between 2015 and 2017.  It is anticipated that each team will be funded at levels between $1 million and $7.5 million per year.